VIEWPOINT MOLECULAR TARGETING INC SBIR Phase II Award, July 2022
A SBIR Phase II contract was awarded to Viewpoint Molecular Targeting, Inc. in July, 2022 for $976,668.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.